Can ALNY's Key Partnerships With Pharma Giants Drive Long-Term Growth?

Alnylam Pharmaceuticals (ALNY) reported strong H1 2025 net product revenues of $1.14 billion, a 47% year-over-year increase, largely propelled by its lead drug Amvuttra, which grew 89% to $801.9 million despite competition from Pfizer and BridgeBio. Future growth is underpinned by key partnerships, including advancing cemdisiran into Phase III studies with Regeneron and progressing zilebesiran for hypertension with Roche, following positive Phase II data and a planned 11,000-patient Phase III outcomes study in late 2025. While ALNY's stock has surged 92.1% year-to-date, its valuation is elevated with a 23.98 price-to-sales ratio, though earnings estimates for 2025 and 2026 have seen significant upward revisions.

Analysis

Alnylam Pharmaceuticals is demonstrating robust top-line growth, with net product revenues increasing 47% year-over-year to $1.14 billion in the first half of 2025, primarily driven by its lead drug, Amvuttra. Amvuttra's sales surged 89% to $801.9 million, indicating strong patient demand despite facing significant competition. The company's future growth is heavily reliant on its strategic partnerships and pipeline, notably the advancement of cemdisiran with Regeneron and zilebesiran with Roche. While zilebesiran's mid-stage study results were encouraging, they failed to meet the pre-specified threshold for statistical significance; however, the partners are proceeding with a large-scale 11,000-patient Phase III study, signaling high conviction in the asset's potential. This pipeline progress is balanced by considerable competitive pressure in the ATTR-CM market from Pfizer’s dominant Vyndaqel ($3.1 billion in H1 2025 sales) and BridgeBio’s rapidly adopted Attruby, both of which offer advantages in oral administration and lower pricing. The market has priced in significant optimism, with ALNY's stock up 92.1% year-to-date and trading at a premium Price-to-Sales multiple of 23.98, well above the industry average of 2.16. This valuation is supported by substantial upward revisions in 2025 and 2026 earnings estimates, which have more than doubled in the past 60 days.

Key Decisions for Investors

• Given the stock's 92.1% year-to-date rally and elevated valuation, investors should consider whether the strong growth from Amvuttra and significant upward earnings revisions sufficiently compensate for the execution risk in the pipeline.
• Closely monitor the progress and data from the planned Phase III ZENITH CV outcomes study for zilebesiran, as its success is a key catalyst required to diversify revenue streams and justify the company's premium valuation.
• Investors should track prescription trends and market share for Amvuttra relative to Pfizer's Vyndaqel and BridgeBio's Attruby, as any erosion in market position due to competitors' pricing or administration advantages could temper future growth expectations.